Evidence map›Paper›PMID 35412053›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2022

First experiences with dynamic renal [

David Kersting, Miriam Sraieb, Robert Seifert, Pedro Fragoso Costa, Sandra Kazek, Lukas Kessler, Lale Umutlu, Wolfgang Peter Fendler, Walter Jentzen, Ken Herrmann and 3 more

Open access · hybridAbstract read
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. PET-based risk stratification for adverse events under [European journal of nuclear medicine and molecular imaging · 2026
    Article
  2. Review
  3. Review
  4. Article
  5. Response to letter to the editor.European journal of nuclear medicine and molecular imaging · 2022
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

David KerstingDepartment of Nuclear Medicine, University Hospital Essen, West German Cancer Center (WTZ), University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany. david.kersting@uni-due.de.ORCID 0000-0002-8451-1830
Miriam SraiebDepartment of Nuclear Medicine, University Hospital Essen, West German Cancer Center (WTZ), University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany.
Robert SeifertDepartment of Nuclear Medicine, University Hospital Essen, West German Cancer Center (WTZ), University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany.
Pedro Fragoso CostaDepartment of Nuclear Medicine, University Hospital Essen, West German Cancer Center (WTZ), University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany.
Sandra KazekDepartment of Nuclear Medicine, University Hospital Essen, West German Cancer Center (WTZ), University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany.
Lukas KesslerDepartment of Nuclear Medicine, University Hospital Essen, West German Cancer Center (WTZ), University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany.
Lale UmutluGerman Cancer Consortium (DKTK, Partner Site Essen/Düsseldorf), Essen, Germany.
Wolfgang Peter FendlerDepartment of Nuclear Medicine, University Hospital Essen, West German Cancer Center (WTZ), University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany.
Walter JentzenDepartment of Nuclear Medicine, University Hospital Essen, West German Cancer Center (WTZ), University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany.
Ken HerrmannDepartment of Nuclear Medicine, University Hospital Essen, West German Cancer Center (WTZ), University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany.
Florian BütherDepartment of Nuclear Medicine, University Hospital Muenster, University of Muenster, Muenster, Germany.
Michael NaderDepartment of Nuclear Medicine, University Hospital Essen, West German Cancer Center (WTZ), University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany.
Christoph RischplerDepartment of Nuclear Medicine, University Hospital Essen, West German Cancer Center (WTZ), University of Duisburg-Essen, Hufelandstrasse 55, 45147, Essen, Germany.
German Cancer Research Center · DEUniversity Hospital Münster · DEWest German Heart and Vascular Center Essen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe determination of the glomerular filtration rate (GFR) is decisive for a variety of clinical issues, for example, to monitor the renal function in radionuclide therapy patients. Renal scintigraphy using glomerularly filtered tracers allows combined acquisition of renograms and GFR estimation but requires repeated blood sampling for several hours. In contrast, dynamic PET imaging using the glomerularly filtered tracer [

methodsDynamic [

resultsPET image interpretation revealed the same findings as conventional scintigraphy (2/12 patients with both- and 1/12 patients with right-sided urinary obstruction). Model fit functions were substantially improved for the modified approach to exclude spill-over. Depending on the modelling approach, GFR

conclusionRenal [

Indexed as

Positron Emission Tomography Computed TomographyRenal Insufficiency, ChronicCreatinineGallium RadioisotopesGlomerular Filtration RateHeterocyclic Compounds, 1-RingHumansKidney1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidCreatinineGallium RadioisotopesHeterocyclic Compounds, 1-RingCompartmental kinetic modellingDOTA PETDynamic PETGlomerular filtration rateRenal PET/CT

Identifiers

PMID35412053
PMCPMC9002049
OpenAlexW4223575226

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.